The use of artificial intelligence (AI) in drug development has been hampered by issues that have caused a gap between AI’s potential and its full utilization in this space.
Peter Madrid
Advertisement
Articles by Peter Madrid
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry
2
Pharma Companies Raise List Prices, Including 16 That Had Agreements to Lower Prices with Trump Administration: Report
3
Henlius Enters Global Exclusive License Agreement with U-mab Biopharma for Best-in-Class Potential Anti-IL-1RAP mAb
4
Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma
5